ERBB2 and breast carcinoma: Although there has been no large‐scale clinical research in breast cancer, research from Sand et al. highlights the potential clinical utility of AZD1775 for overcoming trastuzumab resistance in HER2‐positive breast cancer,29 providing new evidence to support the application of AZD1775 in breast cancer.